First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
The bull case is simple: analysts see revenue climbing from $276M to $670M as recent clinical trials for a new monoclonal antibody showed a 75% efficacy rate, significantly above industry average.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.